Freeze-dried cellular components can be rehydrated to churn out useful proteins.
Researchers at MIT and other institutions have created tiny freeze-dried pellets that include all of the molecular machinery needed to translate DNA into proteins, which could form the basis for on-demand production of drugs and vaccines.
The pellets, which contain dozens of enzymes and other molecules extracted from cells, can be stored for an extended period of time at room temperature. Upon the addition of water and freeze-dried DNA, the pellets begin producing proteins encoded by the DNA.
“It’s a modular system that can be programmed to make what you need, on the spot,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Department of Biological Engineering and Institute for Medical Engineering and Science (IMES). “You could have hundreds of different DNA pellets you can add in the field.”
These pellets, a few millimeters in diameter, could be easily carried by soldiers, astronauts, or health care workers heading to remote areas, says Collins, who is the senior author of a paper describing this strategy in the Sept. 22 online edition of Cell.
The paper’s lead authors are Keith Pardee, an assistant professor at the University of Toronto and former research scientist at Harvard University’s Wyss Institute for Biologically Inspired Engineering; Shimyn Slomovic, an IMES postdoc; Jeong Wook Lee, a Wyss Institute research scientist; and Peter Nguyen, a Wyss Institute Technology Fellow.
Collins and many others in the growing field of synthetic biology have previously designed cells to perform many functions they don’t normally have, such as producing drugs or biofuels. Over the past few years, Collins has shown that this kind of design can also be done outside of cells, by extracting the necessary cellular components and freeze-drying them onto paper or other materials.
“The cell-free extracts consist of a few dozen enzymes, DNA, and RNA, as well as ribosomes and other molecular machines leading to transcription and translation,” Collins says.
In the new study, the researchers took the paper out of the equation: The cellular extracts are simply freeze-dried into pellets, which remain stable for at least a year. To activate protein production, the researchers add water to rehydrate the pellets, along with freeze-dried DNA that encodes the desired protein.
This approach could be useful for generating a wide range of products, including both drugs and molecules that could be used to diagnose illness. In the Cell study, the researchers produced small proteins that could be used as a diphtheria vaccine, as well as antimicrobial peptides, which hold potential to fight bacterial infections.
They also programmed the pellets to generate enzymes that form a multistep metabolic pathway that synthesizes a complex drug known as violacein, which has anticancer and antibiotic activity.
For diagnostic applications, the researchers used the pellets to produce several different types of antibodies, including one that can detect the bacterium Clostridium difficile, which can produce severe inflammation of the colon.
This approach could prove easier than using live cells to generate biopharmaceuticals because the freeze-dried components are easy to store and ship, and they don’t need to be refrigerated.
“Collins and colleagues paint a future where freeze-dried, cell-free biomanufacturing platforms can be used to synthesize therapeutics, vaccines, and biochemicals on demand, without the need for a cold [supply] chain,” says Michael Jewett, an associate professor of chemical and biological engineering at Northwestern University, who was not involved in the research. “By moving manufacturing from the factory to the front lines, we might be able to provide patient-specific medicines where medicines are not available now.”
Collins anticipates that this type of technology should be useful in a variety of settings.
“It could be used in a very simple carry kit for health care workers going in the field in developing regions,” he says. “We think it could be very useful for the military, when you’re going out on a mission in the field, or for hikers and athletes going for long hauls. You could even have it in the back of your car as an expanded first aid kit.”
These pellets could also be incorporated into educational tools — “the biotech equivalent of a chemistry kit,” Collins says. “You could envision using these pellets to allow students to conduct synthetic biology experiments at home, or in middle schools and high schools.”
Another application Collins plans to pursue is integrating the pellets into “smart bandages” that would detect an infection and then begin producing the appropriate antimicrobial peptide to treat the infection.
The Latest on: Biopharmaceuticals on demand
via Google News
The Latest on: Biopharmaceuticals on demand
- Why the Paradigm Biopharmaceuticals share price rocketed 63% higher today on December 17, 2018 at 4:17 pm
The Paradigm Biopharmaceuticals Ltd (ASX ... But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report. […]
- How to Make Biopharmaceuticals Quickly in Small Batches on October 9, 2018 at 7:43 am
A team of researchers has engineered a miniaturized biopharmaceutical “factory” that could ... As published recently in the journal Nature Biotechnology, this on-demand manufacturing system is called ... […]
- A new way to manufacture small batches of biopharmaceuticals on demand on October 1, 2018 at 8:27 am
Biopharmaceuticals, a class of drugs comprising proteins such as antibodies and hormones, represent a fast-growing sector of the pharmaceutical industry. They’re increasingly important for “precision ... […]
- A new way to manufacture small batches of biopharmaceuticals on demand on October 1, 2018 at 8:03 am
MIT chemical engineers have devised a new desktop machine that can be easily reconfigured to manufacture small amounts of different biopharmaceutical drugs. Credit: Felice Frankel, Christine Daniloff, ... […]
- Your Daily Pharma Scoop: Eiger Selloff, Novartis' Cosentyx, RXi Outlines Business Strategy on January 17, 2018 at 5:49 am
Analysis of top Seeking Alpha coverage: Eiger Biopharmaceuticals Today we will discuss the ... approved its ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated] for the on-demand treatment and pro... […]
- Hold On To Nektar Therapeutics: There Is Much More Ammunition Left In Its Partnered Research Programs on November 29, 2017 at 5:26 am
NKTR-214 may help Nektar Therapeutics target a significant unmet demand. Investors, however ... I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship ... […]
- Make biopharmaceuticals on demand by adding water on September 27, 2016 at 12:07 pm
Freeze-dried cellular components can be rehydrated to churn out proteins. It can be used by soldiers, healthcare workers & astronauts Researchers at MIT and other institutions have created tiny freeze ... […]
- Oncolinx Receives Three Months of Free Bench on Demand Space at Mass Innovation Labs on September 21, 2016 at 7:29 am
--(BUSINESS WIRE)--Mass Innovation Labs, an accelerated ... months of free Bench on Demand laboratory space at Mass Innovation Labs, which provides the flexibility and capabilities to meet the needs o... […]
- Portable device produces biologic drugs on demand on July 29, 2016 at 5:04 am
A new, portable production system is designed to manufacture a range of biopharmaceuticals on demand. The principal component of the microbioreactor is a plastic chip with microfluidic circuits (green ... […]
via Bing News